Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line

被引:13
作者
Kang, Chung Hyo [1 ,2 ]
Kim, Yeongrin [1 ,3 ]
Lee, Heung Kyoung [1 ]
Lee, So Myoung [1 ]
Jeong, Hye Gwang [2 ]
Choi, Sang Un [1 ]
Park, Chi Hoon [1 ,3 ]
机构
[1] Korea Res Inst Chem Technol, Therapeut & Biotechnol Div, POB 107, Daejeon 34114, South Korea
[2] Chungnam Natl Univ, Coll Pharm, Daejeon 34134, South Korea
[3] Korea Univ Sci & Technol, Med Chem & Pharmacol, Daejeon 34113, South Korea
关键词
CD19; chimeric-antigen receptor; scFv; FMC63; leukemia;
D O I
10.3390/ijms21239163
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
CD19 is the most promising target for developing chimeric-antigen receptor (CAR) T cells against B-cell leukemic cancer. Currently, two CAR-T-cell products, Kymriah and Yescarta, are approved for leukemia patients, and various anti-CD19 CAR T cells are undergoing clinical trial. Most of these anti-CD19 CAR T cells use FMC63 single-chain variable fragments (scFvs) for binding CD19 expressed on the cancer cell surface. In this study, we screened several known CD19 scFvs for developing anti-CD19 CAR T cells. We used the KHYG-1 NK/T-cell line for screening of CD19 scFvs because it has advantages in terms of cell culture and gene transduction compared to primary T cells. Using our CAR construct backbone, we made anti-CD19 CAR constructs which each had CD19 scFvs including FMC63, B43, 25C1, BLY3, 4G7, HD37, HB12a, and HB12b, then made each anti-CD19 CAR KHYG-1 cells. Interestingly, only FMC63 CAR KHYG-1 and 4G7 CAR KHYG-1 efficiently lysed CD19-positive cell lines. In addition, in Jurkat cell line, only these two CAR Jurkat cell lines secreted IL-2 when co-cultured with CD19-positive cell line, NALM-6. Based on these results, we made FMC63 CAR T cells and 4G7 CAR T cells from PBMC. In in vitro lysis assay, 4G7 CAR T cells lysed CD19-positive cell line as well as FMC63 CAR T cells. In in vivo assay with NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice, 4G7 CAR T cells eradicated NALM-6 as potently as FMC63 CAR T cells. Therefore, we anticipate that 4G7 CAR T cells will show as good a result as FMC63 CAR T cells for B-cell leukemia patients.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 50 条
  • [31] Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells
    Dayagi, Talya Wittmann
    Sherman, Gilad
    Bielorai, Bella
    Adam, Etai
    Besser, Michal J.
    Shimoni, Avichai
    Nagler, Arnon
    Toren, Amos
    Jacoby, Elad
    Avigdor, Abraham
    LEUKEMIA & LYMPHOMA, 2021, 62 (07) : 1692 - 1701
  • [32] Treatment of aggressive T-cell lymphoma/leukemia with anti-CD4 CAR T cells
    Feng, Jia
    Xu, Haichan
    Cinquina, Andrew
    Wu, Zehua
    Zhang, Wenli
    Sun, Lihua
    Chen, Qi
    Tian, Lei
    Song, Le
    Pinz, Kevin G.
    Wada, Masayuki
    Jiang, Xun
    Hanes, William M.
    Ma, Yupo
    Zhang, Hongyu
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [33] Neurotoxicity following CD19/CD28ζ CAR T-cells in children and young adults with B-cell malignancies
    Shalabi, Haneen
    Martin, Staci
    Yates, Bonnie
    Wolters, Pamela L.
    Kaplan, Claire
    Smith, Hannah
    Sesi, Christopher R.
    Jess, Jennifer
    Toledo-Tamula, Mary Ann
    Struemph, Kari
    Delbrook, Cindy P.
    Khan, Omar, I
    Mackall, Crystal L.
    Lee, Daniel W.
    Shah, Nirali N.
    NEURO-ONCOLOGY, 2022, 24 (09) : 1584 - 1597
  • [34] T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 x CD3 or CD19 x CD16
    Poertner, Lisa M.
    Schoenberg, Kathrin
    Hejazi, Maryam
    Bruennert, Daniela
    Neumann, Frank
    Galonska, Lars
    Reusch, Uwe
    Little, Melvyn
    Haas, Rainer
    Uhrberg, Markus
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2012, 61 (10) : 1869 - 1875
  • [35] CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies
    Martyniszyn, Alexandra
    Krahl, Ann-Christin
    Andre, Maya C.
    Hombach, Andreas A.
    Abken, Hinrich
    HUMAN GENE THERAPY, 2017, 28 (12) : 1147 - 1157
  • [36] Characterization of an Anti-CD5 Directed CAR T-Cell against T-Cell Malignancies
    Wada, Masayuki
    Zhang, Hongyu
    Fang, Liu
    Feng, Jia
    Tse, Charlotte Olivia
    Zhang, Wenli
    Chen, Qi
    Sha, Sha
    Cao, Yuanzhen
    Chen, Kevin H.
    Pinz, Kevin G.
    Chen, Xi
    Fan, Xing-Xing
    Jiang, Xun
    Ma, Yupo
    STEM CELL REVIEWS AND REPORTS, 2020, 16 (02) : 369 - 384
  • [37] Direct Delivery of piggyBac CD19 CAR T Cells Has Potent Anti-tumor Activity against ALL Cells in CNS in a Xenograft Mouse Model
    Tanaka, Kuniaki
    Kato, Itaru
    Tanaka, Miyuki
    Morita, Daisuke
    Matsuda, Kazuyuki
    Takahashi, Yoshiyuki
    Nakahata, Tatsutoshi
    Umeda, Katsutsugu
    Hiramatsu, Hidefumi
    Adachi, Souichi
    Takita, Junko
    Nakazawa, Yozo
    MOLECULAR THERAPY-ONCOLYTICS, 2020, 18 : 37 - 46
  • [38] CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies
    Gomes-Silva, Diogo
    Srinivasan, Madhuwanti
    Sharma, Sandhya
    Lee, Ciaran M.
    Wagner, Dimitrios L.
    Davis, Timothy H.
    Rouce, Rayne H.
    Bao, Gang
    Brenner, Malcolm K.
    Mamonkin, Maksim
    BLOOD, 2017, 130 (03) : 285 - 296
  • [39] How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia
    Ruella, Marco
    Gill, Saar
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2015, 15 (06) : 761 - 766
  • [40] Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
    Gust, Juliane
    Hay, Kevin A.
    Hanafi, Laila-Aicha
    Li, Daniel
    Myerson, David
    Gonzalez-Cuyar, Luis F.
    Yeung, Cecilia
    Liles, W. Conrad
    Wurfel, Mark
    Lopez, Jose A.
    Chen, Junmei
    Chung, Dominic
    Harju-Baker, Susanna
    Tzpolat, Tahsin
    Fink, Kathleen R.
    Riddell, Stanley R.
    Maloney, David G.
    Turtle, Cameron J.
    CANCER DISCOVERY, 2017, 7 (12) : 1404 - 1419